Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
about
The kinase Mirk is a potential therapeutic target in osteosarcoma.Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)New targets to treat obesity and the metabolic syndrome.Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescenceMirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancerA dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.The C-terminal region of E1A: a molecular tool for cellular cartography.Association of chromosome 19 to lung cancer genotypes and phenotypes.DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.Annexin A1, Annexin A2, and Dyrk 1B are upregulated during GAS1-induced cell cycle arrest.Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.Emerging Roles of DYRK Kinases in Embryogenesis and Hedgehog Pathway Control.
P2860
Q33521423-9337AEAC-3D5C-4FDF-BA1A-DB66EC24BB08Q33857859-21200C52-6A2A-4856-A2D0-F7D050BECB3FQ36068914-D55B3636-7896-41BC-A25D-346F4579D737Q36544412-96B02FD1-C707-4B89-AB3D-9F8DF789F6FAQ36618381-C82DD446-DA35-4975-AAF9-D0E023835C6AQ36645549-D5EB5944-1DB3-4B7D-A207-C74464A07DC4Q37379468-9793F7C9-8329-45AF-B348-2F1EA18CFE20Q37980172-88814F57-B53D-41AC-A616-3B2BC3F132DCQ38485902-C5B31324-7912-48A0-8395-A806894C2712Q38866748-31E2CCC5-6737-4E07-A5E0-9D8BB497B76FQ41782221-C1AE9F12-F475-474E-9A52-19C2B2C83A62Q42708880-DA96A41B-DB89-4749-9726-2774BC730FABQ46250363-A2F2E46D-0ED5-436D-9FA5-E2B2EB3A9E0FQ47654334-D96546F5-A2F6-4D90-992F-35108B920D5DQ52641599-3169634A-DD00-4779-8724-76A0D41A58E8Q54117942-4CF331FF-0BB8-4816-B095-B55016CB3601
P2860
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mirk/Dyrk1B, a novel therapeut ...... n-small cell lung cancer cells
@en
Mirk/Dyrk1B, a novel therapeut ...... -small cell lung cancer cells.
@nl
type
label
Mirk/Dyrk1B, a novel therapeut ...... n-small cell lung cancer cells
@en
Mirk/Dyrk1B, a novel therapeut ...... -small cell lung cancer cells.
@nl
prefLabel
Mirk/Dyrk1B, a novel therapeut ...... n-small cell lung cancer cells
@en
Mirk/Dyrk1B, a novel therapeut ...... -small cell lung cancer cells.
@nl
P2093
P2860
P356
P1476
Mirk/Dyrk1B, a novel therapeut ...... n-small cell lung cancer cells
@en
P2093
Bhupendra Rawal
Eric B Haura
Gerold Bepler
Jingchun Gao
Michael J Schell
Zhong Zheng
P2860
P304
P356
10.4161/CBT.8.17.9322
P577
2009-09-20T00:00:00Z